Liu, Wei
Xiong, Wei
Liu, Wenxin
Hirakawa, Jotaro
Kawashima, Hiroto http://orcid.org/0000-0002-6599-7329
Funding for this research was provided by:
Japan Agency for Medical Research and Development (20ae0101034h0005, 22ae0121017h0002, 22ym0126065h0001)
MEXT | Japan Society for the Promotion of Science (20H03379)
Article History
Received: 30 November 2022
Accepted: 17 September 2023
First Online: 21 September 2023
Competing interests
: This study was supported in part by the Japan Agency for Medical Research and Development (AMED; Grant Numbers 20ae0101034h0005, 22ae0121017h0002, and 22ym0126065h0001 to H.K.), JSPS KAKENHI (Grant Number 20H03379 to H.K.), and Institute for Advanced Academic Research of Chiba University (to H.K.). H.K. is an inventor on a PCT patent application (PCT/JP2021/036893) regarding the development and application of SF1 antibody filed by Chiba University. The other authors declare that they have no competing interests with the contents of this article.